\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u4e34\u5e8a\u8bd5\u9a8c\u8054\u76df\uff08ACTC\uff09\u3001\u536b\u6750\u682a\u5f0f\u4f1a\u793e\uff08\u603b\u90e8\uff1a\u4e1c\u4eac\uff0c\u9996\u5e2d\u6267\u884c\u5b98\uff1a\u5185\u85e4\u6674\u592b\uff0c\u201c\u536b\u6750\u201d\uff09\u548c\u6e24\u5065\uff08Nasdaq\uff1aBIIB\uff0c\u603b\u90e8\uff1a\u7f8e\u56fd\u9a6c\u8428\u8bf8\u585e\u5dde\u5251\u6865\uff0c\u9996\u5e2d\u6267\u884c\u5b98\uff1a\u51af\u7eb3\u73ba\uff0c\u201c\u6e24\u5065\u201d\uff09\u8fd1\u65e5\u5ba3\u5e03\uff0c\u5728\u7f8e\u56fd\uff0c\u9488\u5bf9\u4e34\u5e8a\u524d\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\uff08AD\uff09\u4e2a\u4f53\uff08\u4e34\u5e8a\u4e0a\u6b63\u5e38\uff0c\u4f46\u5b58\u5728\u8111\u6dc0\u7c89\u6837\u86cb\u767d\u6c34\u5e73\u4e2d\u7b49\u6216\u5347\u9ad8\uff09\uff0c\u542f\u52a8\u5bf9\u6297\u6dc0\u7c89\u6837\u86cb\u767d\u03b2\uff08A\u03b2\uff09\u539f\u7ea4\u7ef4\u6297\u4f53BAN2401\u7684\u4e00\u9879\u65b0III\u671f\u4e34\u5e8a\u7814\u7a76\uff08AHEAD 3-45\uff09\u3002\u76ee\u524d\uff0c\u57fa\u4e8eII\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7814\u7a76201\uff09\u7684\u7ed3\u679c\uff0c\u5728\u5bf9\u75c7\u72b6\u6027\u65e9\u671fAD\uff08Clarity AD\uff09\u7684\u5173\u952eIII\u671f\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u8fdb\u884c\u4e2d\u3002AHEAD 3-45\u5c06\u5728\u7f8e\u56fd\u3001\u65e5\u672c\u3001\u52a0\u62ff\u5927\u3001\u6fb3\u5927\u5229\u4e9a\u3001\u65b0\u52a0\u5761\u548c\u6b27\u6d32\u8fdb\u884c\u3002<\/p>\n
AHEAD 3-45\u662f\u4e00\u9879\u7531\u56fd\u7acb\u536b\u751f\u7814\u7a76\u9662\u4e0b\u5c5e\u7684\u56fd\u5bb6\u8870\u8001\u7814\u7a76\u6240\u8d44\u52a9\u7684ACTC\u548c\u536b\u6750\u516c\u79c1\u5408\u4f5c\u8fdb\u884c\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\u3002AHEAD 3-45\u7684\u666e\u901a\u7b5b\u9009\u671f\u540e\uff0c\u53d7\u8bd5\u8005\u5c06\u88ab\u62db\u52df\u8fdb\u5165\u4e24\u9879\u57fa\u4e8e\u8111\u6dc0\u7c89\u6837\u86cb\u767d\u6c34\u5e73\u7684\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u8bd5\u9a8c\u4e4b\u4e00\uff1aA45\u8bd5\u9a8c\u548cA3\u8bd5\u9a8c\u3002\u7814\u7a76\u5171\u62db\u52df1400\u540d\u53d7\u8bd5\u8005\uff0c\u63a5\u53d7\u4e3a\u671f216\u5468\u7684BAN2401\u6cbb\u7597\u3002A45\u8bd5\u9a8c\u5c06\u62db\u52df\u8111\u6dc0\u7c89\u6837\u86cb\u767d\u6c34\u5e73\u5347\u9ad8\u7684\u3001\u8ba4\u77e5\u672a\u53d7\u635f\u7684\u53d7\u8bd5\u8005\uff0c\u65e8\u5728BAN2401\u7ed9\u836f\uff0c\u53ef\u9884\u9632\u8ba4\u77e5\u8870\u9000\u548c\u6291\u5236\u8111AD\u75c5\u7406\u7684\u8fdb\u5c55\u3002A45\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\uff0c\u5728\u6cbb\u7597\u7684\u7b2c216\u5468\u65f6\uff0c5\u5206\u5236\u4e34\u5e8a\u524d\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u8ba4\u77e5\u7efc\u5408\u8bc4\u5206\uff08PACC5\uff09\u8f83\u57fa\u7ebf\u7684\u53d8\u5316\uff1b\u6b21\u8981\u7ec8\u70b9\u662f\u6b63\u7535\u5b50\u53d1\u5c04\u65ad\u5c42\u626b\u63cf\uff08PET\uff09\u68c0\u6d4b\u7684\u8111A\u03b2\u3001tau\u6c34\u5e73\u548c\u8ba4\u77e5\u529f\u80fd\u6307\u6807\uff08\u53d7\u8bd5\u8005\u548c\u7814\u7a76\u8005\u5171\u540c\u62a5\u544a\u7684\u7ed3\u679c\uff09\u8f83\u57fa\u7ebf\u7684\u53d8\u5316\u3002A3\u8bd5\u9a8c\u5c06\u62db\u52df\u8111\u6dc0\u7c89\u6837\u86cb\u767d\u91cf\u4e2d\u7b49\u3001\u5b58\u5728\u8fdb\u4e00\u6b65A\u03b2\u805a\u96c6\u9ad8\u98ce\u9669\u7684\u8ba4\u77e5\u672a\u53d7\u635f\u53d7\u8bd5\u8005\u3002A3\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u8111A\u03b2 PET\u6c34\u5e73\u8f83\u57fa\u7ebf\u7684\u53d8\u5316\uff1b\u6b21\u8981\u7ec8\u70b9\u662f\u8111tau PET\u6c34\u5e73\u8f83\u57fa\u7ebf\u7684\u53d8\u5316\u3002\u4e24\u9879\u8bd5\u9a8c\u5747\u5305\u62ec\u4e00\u4e9b\u989d\u5916\u4e34\u5e8a\u8bc4\u4f30\u91cf\u8868\u3001\u5f71\u50cf\u3001\u8840\u6db2\u751f\u7269\u6807\u5fd7\u7269\u548c\u8111\u810a\u6db2\uff08CSF\uff09\uff0c\u4f5c\u4e3a\u63a2\u7d22\u6027\u7ec8\u70b9\u3002ATN\uff08A\u03b2\uff0cTau\uff0c\u795e\u7ecf\u9000\u884c\u6027\u53d8\uff09\u6210\u50cf\u548c\u4f53\u6db2\uff08\u5c24\u5176\u662fCSF\uff09\u751f\u7269\u6807\u5fd7\u7269\u7ec4\uff08\u6807\u5fd7\u7269\u5305\u62ecA\u03b2 1-42\u3001A\u03b2 1-40\u3001t-tau\u3001p-tau\u3001\u795e\u7ecf\u9897\u7c92\u86cb\u767d\u3001\u795e\u7ecf\u4e1d\u8f7b\u94fe\uff09\u5c06\u7528\u4e8e\u8bc4\u4f30\u5bf9AD\u75c5\u7406\u751f\u7406\u8fdb\u5c55\u7684\u7597\u6548\u3002<\/p>\n
\u201c\u5e0c\u671b\u5728\u75be\u75c5\u8fc7\u7a0b\u4e2d\u5c3d\u65e9\u5f00\u59cb\u6cbb\u7597\u53ef\u80fd\u6709\u5229\u4e8e\u9884\u9632\u672a\u6765\u8ba4\u77e5\u51cf\u9000\u3002AHEAD 3-45\u5e94\u63d0\u4f9b\u6700\u4f73\u5e72\u9884\u6297\u6dc0\u7c89\u6837\u86cb\u767d\u6cbb\u7597\u65f6\u95f4\u7684\u5173\u952e\u7b54\u6848\u201d\uff0cACTC\u5e03\u91cc\u683c\u59c6\u5987\u5973\u533b\u9662\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u7814\u7a76\u548c\u6cbb\u7597\u4e2d\u5fc3\u4e3b\u4efb\u548c\u8054\u5408\u9996\u5e2d\u7814\u7a76\u5458Reisa Sperling\u535a\u58eb\u79f0\u3002<\/p>\n
\u5357\u52a0\u5dde\u5927\u5b66\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u6cbb\u7597\u7814\u7a76\u6240\uff08ACTC\u534f\u8c03\u4e2d\u5fc3\uff09\u4e3b\u4efbAisen\u535a\u58eb\u6307\u51fa\uff0c\u201cACTC\u7684\u4f7f\u547d\u5305\u62ec\u53d1\u5c55\u516c\u79c1\u5408\u4f5c\u4f19\u4f34\u5173\u7cfb\uff0c\u5f00\u5c55\u6709\u524d\u666f\u7684\u5019\u9009\u7597\u6cd5\u7684\u8bd5\u9a8c\u3002AHEAD 3-45\u662f\u6211\u4eec\u5728\u5bf9\u6297\u963f\u5c14\u8328\u6d77\u9ed8\u6c0f\u75c5\u65b9\u9762\u9700\u8981\u7684\u5408\u4f5c\u7c7b\u578b\u3002\u201d<\/p>\n
\u201c\u901a\u8fc7\u4e0eACTC\u7684\u5408\u4f5c\uff0c\u542f\u52a8BAN2401\u6cbb\u7597\u6700\u65e9\u671f\u9636\u6bb5AD\u7684AHEAD 3-45\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5bf9\u6211\u4eec\u6765\u8bf4\u662f\u4e00\u4e2a\u6fc0\u52a8\u4eba\u5fc3\u7684\u65f6\u523b\u3002\u201d\u00a0\u536b\u6750\u795e\u7ecf\u5b66\u4e1a\u52a1\u90e8\u9996\u5e2d\u4e34\u5e8a\u5b98\u517c\u9996\u5e2d\u533b\u5b66\u5b98Lynn Kramer\u535a\u58eb\u8bf4\uff0c\u201c\u8fd9\u4ee3\u8868\u7740\u4e0b\u4e00\u6b65\u5c06\u4f7f\u7528\u751f\u7269\u6807\u5fd7\u7269\u7ec4\u5f00\u53d1AD\u7684\u7cbe\u51c6\u7597\u6cd5\uff0c\u4f5c\u4e3a\u6211\u4eec\u4eba\u7c7b\u536b\u751f\u4fdd\u5065\u4f7f\u547d\u7684\u4e00\u90e8\u5206\uff1b\u6211\u4eec\u81f4\u529b\u4e8e\u4e3a\u5168\u7403\u7684\u60a3\u8005\u3001\u4ed6\u4eec\u7684\u5bb6\u4eba\u548c\u533b\u7597\u4fdd\u5065\u4e13\u4e1a\u4eba\u5458\u5e26\u6765\u6539\u53d8\u3002\u201d<\/p>\n
\u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\uff1ahttps:\/www.a3a45.org\/<\/u><\/p>\n
BAN2401\u662f\u4e00\u79cd\u901a\u8fc7\u536b\u6750\u548cBioArctic AB\uff08\u745e\u5178\uff09\u5408\u4f5c\u7814\u7a76\u83b7\u5f97\u7684\u4eba\u6e90\u5316\u3001\u5355\u514b\u9686\u3001\u6297A\u03b2\u53ef\u6eb6\u6027\u805a\u96c6\u4f53\uff08\u539f\u7ea4\u7ef4\uff09\u6297\u4f53\u3002BAN2401\u9009\u62e9\u6027\u5730\u7ed3\u5408\uff0c\u4ee5\u4e2d\u548c\u5e76\u6d88\u9664\u6bd2\u6027A\u03b2\u539f\u7ea4\u7ef4\uff08\u88ab\u89c6\u4e3aAD\u7684\u81f4\u75c5\u56e0\u7d20\uff09\u3002\u56e0\u6b64\uff0cBAN2401\u53ef\u80fd\u4f1a\u5bf9\u75be\u75c5\u75c5\u7406\u4ea7\u751f\u5f71\u54cd\uff0c\u5e76\u51cf\u7f13\u75be\u75c5\u7684\u8fdb\u5c55\u3002\u4f5c\u4e3a\u7b2c\u4e00\u9879\u5bf9\u65e9\u671fAD\u672b\u671f\u5927\u89c4\u6a21\u7684\u4e34\u5e8a\u7814\u7a76\uff0c201\u7814\u7a76\u663e\u793a\u7edf\u8ba1\u5b66\u663e\u8457\u7684\u51cf\u7f13\u75be\u75c5\u8fdb\u5c55\u548c\u964d\u4f4e\u8111A\u03b2\u79ef\u805a\uff0c\u5e76\u6210\u529f\u5730\u663e\u793a\u51fa\u75be\u75c5\u4fee\u9970\u6cbb\u7597\u7684\u6548\u5e94\u3002\u5176\u4e0e201\u5f00\u653e\u6807\u7b7e\u5ef6\u4f38\uff08OLE\uff09\u7814\u7a76\uff08\u5f00\u653e\u6807\u7b7e\u7ee7\u7eed\u7ed9\u836f\u7814\u7a76\uff09\u548c\u4e00\u9879\u5173\u952e\u4e34\u5e8a\u7814\u7a76\uff08Clarity AD\uff09\u4e00\u8d77\u8fdb\u884c\u3002\u536b\u6750\u548c\u6e24\u5065\u5df2\u5f00\u59cb\u5408\u4f5c\u7814\u53d1BAN2401\u5e76\u5c06\u5176\u5546\u4e1a\u5316\u3002<\/p>\n
[<\/strong>\u7f16\u8005\u6ce8]<\/strong><\/p>\n \u7531\u56fd\u7acb\u536b\u751f\u7814\u7a76\u9662\u56fd\u5bb6\u8870\u8001\u7814\u7a76\u6240\u8d44\u52a9\uff08\u6388\u6743\u53f7\u4e3aU24AG057437\uff09\u7684ACTC\uff0c\u4e3a\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u53ca\u76f8\u5173\u75f4\u5446\u7684\u5b66\u672f\u4e34\u5e8a\u8bd5\u9a8c\u63d0\u4f9b\u57fa\u7840\u8bbe\u65bd\u3002\u8be5\u8054\u76df\u7684\u5de5\u4f5c\u5730\u70b9\u4f4d\u4e8e\u5357\u52a0\u5dde\u5927\u5b66\u3001\u54c8\u4f5b\u5927\u5b66\u548c\u6885\u5965\u8bca\u6240\uff0c\u5305\u62ec\u652f\u6301\u4e34\u5e8a\u8bd5\u9a8c\u8bbe\u8ba1\u3001\u751f\u7269\u7edf\u8ba1\u5b66\u3001\u4fe1\u606f\u5b66\u3001\u533b\u7597\u5b89\u5168\u3001\u76d1\u7ba1\u76d1\u7763\u3001\u62db\u52df\u3001\u4e34\u5e8a\u64cd\u4f5c\u3001\u6570\u636e\u7ba1\u7406\u3001\u73b0\u573a\u76d1\u6d4b\u3001\u751f\u7269\u6807\u5fd7\u7269\u5b9e\u9a8c\u5ba4\u548c\u50a8\u5b58\u5e93\u3001\u4ee5\u53ca\u795e\u7ecf\u6210\u50cf\u7684\u4e13\u5bb6\u5355\u4f4d\u3002ACTC\u5305\u62ec\u7f8e\u56fd\u768435\u4e2a\u4e3b\u8981\u4e34\u5e8a\u4e2d\u5fc3\u3002<\/p>\n \u536b\u6750\u682a\u5f0f\u4f1a\u793e\u662f\u603b\u90e8\u4f4d\u4e8e\u65e5\u672c\u7684\u9886\u5148\u5168\u7403\u5236\u836f\u516c\u53f8\u3002\u536b\u6750\u57fa\u4e8e\u5173\u5fc3\u4eba\u7c7b\u5065\u5eb7\uff08hhc<\/em>\uff09\u7684\u4f01\u4e1a\u7406\u5ff5\uff0c\u5c06\u60a3\u8005\u53ca\u5bb6\u5c5e\u7684\u5229\u76ca\u653e\u5728\u9996\u4f4d\uff0c\u5e76\u4e3a\u63d0\u5347\u5176\u798f\u7949\u505a\u51fa\u8d21\u732e\u3002\u51ed\u501f\u7814\u53d1\u673a\u6784\u3001\u751f\u4ea7\u57fa\u5730\u548c\u9500\u552e\u9644\u5c5e\u516c\u53f8\u7684\u5168\u7403\u7f51\u7edc\uff0c\u81f4\u529b\u4e8e\u901a\u8fc7\u9488\u5bf9\u533b\u7597\u9700\u6c42\u672a\u5f97\u5230\u5145\u5206\u6ee1\u8db3\u7684\u75be\u75c5\u63d0\u4f9b\u521b\u65b0\u4ea7\u54c1\uff0c\u6765\u5b9e\u73b0\u6211\u4eec\u5173\u5fc3\u4eba\u7c7b\u5065\u5eb7\u7684\u7406\u5ff5\uff0c\u6211\u4eec\u5c24\u5176\u4fa7\u91cd\u4e8e\u795e\u7ecf\u548c\u80bf\u7624\u6218\u7565\u9886\u57df\u3002<\/p>\n \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u901a\u8fc7\u5229\u7528\u4ece\u5b89\u7406\u7533\u00ae\uff08\u4e00\u79cd\u6cbb\u7597\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u548c\u8def\u6613\u4f53\u75f4\u5446\u7684\u836f\u7269\uff09\u7684\u7814\u53d1\u548c\u9500\u552e\u8bb8\u53ef\u4e2d\u83b7\u5f97\u7684\u7ecf\u9a8c\uff0c\u536b\u6750\u65e8\u5728\u5efa\u7acb\u201c\u536b\u6750\u75f4\u5446\u5e73\u53f0\u201d\u3002\u901a\u8fc7\u5e73\u53f0\uff0c\u536b\u6750\u8ba1\u5212\u901a\u8fc7\u4e0e\u5408\u4f5c\u4f19\u4f34\uff08\u5982\u533b\u7597\u7ec4\u7ec7\u3001\u8bca\u65ad\u5f00\u53d1\u516c\u53f8\u3001\u7814\u7a76\u7ec4\u7ec7\u548c\u751f\u7269\u98ce\u9669\u6295\u8d44\u516c\u53f8\uff09\u4ee5\u53ca\u79c1\u4eba\u4fdd\u9669\u673a\u6784\u3001\u91d1\u878d\u673a\u6784\u3001\u5065\u8eab\u4ff1\u4e50\u90e8\u3001\u6c7d\u8f66\u5236\u9020\u5546\u3001\u96f6\u552e\u5546\u548c\u62a4\u7406\u673a\u6784\u5408\u4f5c\uff0c\u7ecf\u8fc7\u6784\u5efa\u201c\u75f4\u5446\u751f\u6001\u7cfb\u7edf\u201d\uff0c\u4e3a\u63d0\u5347\u75f4\u5446\u60a3\u8005\u53ca\u5176\u5bb6\u5c5e\u7684\u798f\u7949\u505a\u51fa\u8d21\u732e\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u5173\u4e8e\u536b\u6750\u682a\u5f0f\u4f1a\u793e\u7684\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95eehttps:\/\/www.eisai.com\/<\/a>\u3002<\/p>\n \u6e24\u5065\u7684\u4f7f\u547d\u6e05\u6670\u800c\u660e\u786e\uff1a\u6210\u4e3a\u795e\u7ecf\u79d1\u5b66\u9886\u57df\u7684\u5148\u950b\u3002\u6e24\u5065\u4e3a\u60a3\u6709\u4e25\u91cd\u795e\u7ecf\u75be\u75c5\u548c\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u4ee5\u53ca\u76f8\u5173\u6cbb\u7597\u6027\u75be\u75c5\u7684\u60a3\u8005\u53d1\u73b0\u3001\u7814\u53d1\u548c\u63d0\u4f9b\u5168\u7403\u521b\u65b0\u7597\u6cd5\u3002\u4f5c\u4e3a\u4e16\u754c\u4e0a\u6700\u65e9\u7684\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8\u4e4b\u4e00\uff0c\u6e24\u5065\u4e8e1978\u5e74\u7531Charles Weissmann\u3001Heinz Schaller\u3001Kenneth Murray\u4ee5\u53ca\u8bfa\u8d1d\u5c14\u5956\u83b7\u5f97\u8005Walter Gilbert\u548cPhillip Sharp\u521b\u7acb\u3002\u5982\u4eca\uff0c\u6e24\u5065\u62e5\u6709\u6cbb\u7597\u591a\u53d1\u6027\u786c\u5316\u75c7\u7684\u9886\u5148\u836f\u7269\u7ec4\u5408\uff0c\u5df2\u63a8\u51fa\u7b2c\u4e00\u79cd\u7ecf\u6279\u51c6\u7684\u810a\u9ad3\u6027\u808c\u8089\u840e\u7f29\u75c7\u6cbb\u7597\u65b9\u6cd5\uff0c\u5c06\u5148\u8fdb\u751f\u7269\u5236\u54c1\u7684\u751f\u7269\u4eff\u5236\u836f\u5546\u4e1a\u5316\uff0c\u4ee5\u53ca\u4fa7\u91cd\u4e8e\u63a8\u8fdb\u591a\u53d1\u6027\u786c\u5316\u75c7\u548c\u795e\u7ecf\u514d\u75ab\u5b66\u3001\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u548c\u75f4\u5446\u3001\u795e\u7ecf\u808c\u8089\u75be\u75c5\u3001\u8fd0\u52a8\u969c\u788d\u3001\u773c\u79d1\u5b66\u3001\u514d\u75ab\u5b66\u3001\u795e\u7ecf\u8ba4\u77e5\u969c\u788d\u3001\u6025\u6027\u795e\u7ecf\u5b66\u548c\u75bc\u75db\u7684\u7814\u7a76\u8ba1\u5212\u3002<\/p>\n \u6211\u4eec\u5c06\u5b9a\u671f\u5728https:\/\/www.biogen.com<\/a>\u7f51\u7ad9\u4e0a\u53d1\u5e03\u5bf9\u6295\u8d44\u8005\u53ef\u80fd\u91cd\u8981\u7684\u4fe1\u606f\u3002\u5728\u793e\u4ea4\u5a92\u4f53\u4e0a\u5173\u6ce8\u6211\u4eec-\u63a8\u7279<\/u><\/a>\u3001\u9886\u82f1<\/u><\/a>\u3001\u8138\u4e66<\/u><\/a>\u3001YouTube<\/a><\/u>\u3002<\/p>\n NIA\u662fNIH\u768427\u4e2a\u7814\u7a76\u6240\u548c\u4e2d\u5fc3\u4e4b\u4e00\uff0c\u9886\u5bfc\u4e00\u9879\u5e7f\u6cdb\u7684\u79d1\u5b66\u5de5\u4f5c\uff0c\u4ee5\u4e86\u89e3\u8870\u8001\u672c\u8d28\uff0c\u5e76\u5ef6\u957f\u5065\u5eb7\u6709\u6548\u7684\u5bff\u547d\u3002NIA\u662f\u652f\u6301\u548c\u5f00\u5c55\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u7814\u7a76\u7684\u4e3b\u8981\u8054\u90a6\u673a\u6784\u3002\u56fd\u7acb\u536b\u751f\u7814\u7a76\u9662\u3001\u56fd\u5bb6\u8870\u8001\u7814\u7a76\u6240\u6b63\u5728\u4e3aA45\u7814\u7a76\uff08\u6388\u6743\u53f7\uff1aR01AG061848\uff09\u548cA3\u7814\u7a76\uff08\u6388\u6743\u53f7\uff1aR01AG054029\uff09\u63d0\u4f9b\u8d44\u91d1\u3002<\/p>\n PACC5\u4f5c\u4e3a\u4e00\u9879\u7efc\u5408\u8bc4\u5206\uff0c\u7528\u4e8e\u8bc4\u4f30\u8ba4\u77e5\u51cf\u9000\u7684\u4e25\u91cd\u7a0b\u5ea6\uff0c\u4ee5\u4fbf\u80fd\u591f\u5728\u4e34\u5e8a\u524dAD\u9636\u6bb5\u5bf9\u4e34\u5e8a\u529f\u80fd\u53d8\u5316\u8fdb\u884c\u9ad8\u5ea6\u654f\u611f\u68c0\u6d4b\u3002<\/p>\n \u8ba4\u77e5\u529f\u80fd\u6307\u6570\u662f\u4e00\u79cd\u8bc4\u4f30\u6307\u6570\uff0c\u7528\u4e8e\u8bc4\u4f30\u65e5\u5e38\u751f\u6d3b\u4e2d\u6267\u884c\u9ad8\u7ea7\u529f\u80fd\u4efb\u52a1\u7684\u80fd\u529b\u548c\u4e00\u822c\u8ba4\u77e5\u529f\u80fd\u3002<\/p>\n Biogen Safe Harbor<\/strong> \u963f\u5c14\u5179\u6d77\u9ed8\u75c5\u4e34\u5e8a\u8bd5\u9a8c\u8054\u76df\uff08ACTC\uff09\u3001\u536b\u6750\u682a\u5f0f\u4f1a\u793e\uff08\u603b\u90e8\uff1a\u4e1c\u4eac\uff0c\u9996\u5e2d\u6267\u884c\u5b98\uff1a\u5185\u85e4\u6674\u592b\uff0c\u201c\u536b\u6750\u201d\uff09\u548c\u6e24\u5065\uff08Nasdaq\uff1aBIIB\uff0c\u603b\u90e8\uff1a\u7f8e\u56fd\u9a6c\u8428\u8bf8\u585e\u5dde\u5251\u6865\uff0c\u9996\u5e2d\u6267\u884c\u5b98\uff1a\u51af\u7eb3\u73ba\uff0c\u201c\u6e24\u5065\u201d\uff09\u8fd1\u65e5\u5ba3\u5e03\uff0c\u5728\u7f8e\u56fd\uff0c\u9488\u5bf9\u4e34\u5e8a\u524d\u963f\u5c14\u5179\u6d77\u9ed8\u75c5\uff08AD\uff09\u4e2a\u4f53\uff08\u4e34\u5e8a\u4e0a\u6b63\u5e38\uff0c\u4f46\u5b58\u5728\u8111\u6dc0\u7c89\u6837\u86cb\u767d\u6c34\u5e73\u4e2d\u7b49\u6216\u5347\u9ad8\uff09\uff0c\u542f\u52a8\u5bf9\u6297\u6dc0\u7c89\u6837\u86cb\u767d\u03b2\uff08A\u03b2\uff09\u539f\u7ea4\u7ef4\u6297\u4f53BAN2401\u7684\u4e00\u9879\u65b0III\u671f\u4e34\u5e8a\u7814\u7a76\uff08AHEAD 3-45\uff09\u3002\u76ee\u524d\uff0c\u57fa\u4e8eII\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7814\u7a76201\uff09\u7684\u7ed3\u679c\uff0c\u5728\u5bf9\u75c7\u72b6\u6027\u65e9\u671fAD\uff08Clarity AD\uff09\u7684\u5173\u952eIII\u671f\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u8fdb\u884c\u4e2d\u3002AHEAD 3-45\u5c06\u5728\u7f8e\u56fd\u3001\u65e5\u672c\u3001\u52a0\u62ff\u5927\u3001\u6fb3\u5927\u5229\u4e9a\u3001\u65b0\u52a0\u5761\u548c\u6b27\u6d32\u8fdb\u884c\u3002<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-2714","post","type-post","status-publish","format-standard","hentry","category-news-zh"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2714"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=2714"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2714\/revisions"}],"predecessor-version":[{"id":2716,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2714\/revisions\/2716"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=2714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=2714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=2714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
\n
\n
\n
\nThis news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the potential clinical effects of BAN2401; the potential benefits, safety, and efficacy of BAN2401; the clinical development program for BAN2401, including the AHEAD 3-45 study and the Clarity AD study; the results of the Phase II study of BAN2401; the identification and treatment of AD; the anticipated benefits and potential of Biogen\u2019s collaboration arrangements with Eisai; the potential of Biogen\u2019s commercial business and pipeline programs, including BAN2401; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u00a0\u201cpotential,\u201d \u201cwill,\u201d \u201cwould\u201dand other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
\nThese statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis, or results obtained during clinical trials; the occurrence of adverse safety events; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; risks of unexpected costs or delays; the risk of other unexpected hurdles; failure to protect and enforce Biogen\u2019s data, intellectual property, and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; third party collaboration risks; and the direct and indirect impacts of the ongoing COVID-19 pandemic on Biogen\u2019s business, results of operations, and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen\u2019s expectations in any forwardlooking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen\u2019s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen\u2019s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.<\/p>\n","protected":false},"excerpt":{"rendered":"